Kenneth Brian Gordon, MD

Chair, Professor

Request an Appointment

Location

Dermatology - Froedtert Cancer Center
8800 West Doyne Ave.
Milwaukee, WI 53226

Specialties

Dermatology

New & Established Patients Call

(414) 805-3666

Overview

Diseases and Conditions

Inflammatory Skin Disorders
Psoriasis
Psoriatic Arthritis

Treatments and Services

Virtual Visit

Patients Ages Seen

Adult
Senior

Languages

English

Hospital Affiliations

Froedtert Hospital – Milwaukee
Zablocki VA Medical Center – Milwaukee

Board Certifications

Dermatology

Clinic Locations

Dermatology - Froedtert Cancer Center

8800 West Doyne Ave.
Milwaukee, WI 53226
(414) 805-5320
Get Directions

Biography

Education and Training

Doctor of Medicine - Columbia University College of Physicians and Surgeons - New York, NY (1990)
Residency in Internal Medicine - Beth Israel Hospital - Boston, MA (1990-1993)
Residency in Dermatology - Northwestern University Medical School - Chicago, IL (1993-1997)
Fellowship in Immunology - Northwestern University Medical School - Chicago, IL (1995-1997)

Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials.

(Gordon KB, Langley RG, Warren RB, Okubo Y, Stein Gold L, Merola JF, Peterson L, Wixted K, Cross N, Deherder D, Thaçi D.) JAMA Dermatol. 2022 May 11 PMID: 35544084 SCOPUS ID: 2-s2.0-85130365798 05/12/2022
Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis.

(Gordon KB, Lebwohl M, Papp KA, Bachelez H, Wu JJ, Langley RG, Blauvelt A, Kaplan B, Shah M, Zhao Y, Sinvhal R, Reich K.) Br J Dermatol. 2022 03;186(3):466-475 PMID: 34652810 SCOPUS ID: 2-s2.0-85119997467 10/16/2021
Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study

(Crowley JJ, Langley RG, Gordon KB, Pinter A, Ferris LK, Rubant S, Photowala H, Xue Z, Wu T, Zhan T, Beeck S, Shah M, Warren RB.) Dermatology and Therapy. February 2022;12(2):561-575 SCOPUS ID: 2-s2.0-85123243722 02/01/2022
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial

(Thaçi D, Strober B, Gordon KB, Foley P, Gooderham M, Morita A, Papp KA, Puig L, Menter MA, Colombo MJ, Elbez Y, Kisa RM, Ye J, Napoli AA, Wei L, Banerjee S, Merola JF, Gottlieb AB.) Dermatology and Therapy. February 2022;12(2):495-510 SCOPUS ID: 2-s2.0-85123098014 02/01/2022
Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2.

(Reich K, Gordon KB, Strober BE, Armstrong AW, Miller M, Shen YK, You Y, Han C, Yang YW, Foley P, Griffiths CEM.) Br J Dermatol. 2021 12;185(6):1146-1159 PMID: 34105767 SCOPUS ID: 2-s2.0-85114484669 06/10/2021
Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis.

(Blauvelt A, Gordon KB, Lee P, Bagel J, Sofen H, Lockshin B, Soliman AM, Geng Z, Zhan T, Alperovich G, Stein Gold L.) J Dermatolog Treat. 2021 May 05:1-9 PMID: 33947295 05/06/2021
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.

(Reich K, Papp KA, Blauvelt A, Langley RG, Armstrong A, Warren RB, Gordon KB, Merola JF, Okubo Y, Madden C, Wang M, Cioffi C, Vanvoorden V, Lebwohl M.) Lancet. 2021 02 06;397(10273):487-498 PMID: 33549193 SCOPUS ID: 2-s2.0-85100417985 02/08/2021
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.

(Gordon KB, Foley P, Krueger JG, Pinter A, Reich K, Vender R, Vanvoorden V, Madden C, White K, Cioffi C, Blauvelt A.) Lancet. 2021 02 06;397(10273):475-486 PMID: 33549192 SCOPUS ID: 2-s2.0-85100381587 02/08/2021
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial

(Gordon KB, Foley P, Krueger JG, Pinter A, Reich K, Vender R, Vanvoorden V, Madden C, White K, Cioffi C, Blauvelt A.) The Lancet. 6 February 2021;397(10273):475-486 SCOPUS ID: 2-s2.0-85100381587 02/06/2021
Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis

(Blauvelt A, Gordon KB, Lee P, Bagel J, Sofen H, Lockshin B, Soliman AM, Geng Z, Zhan T, Alperovich G, Stein Gold L.) Journal of Dermatological Treatment. 2021 SCOPUS ID: 2-s2.0-85105382915 01/01/2021
Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials.

(Augustin M, Lambert J, Zema C, Thompson EHZ, Yang M, Wu EQ, Garcia-Horton V, Geng Z, Valdes JM, Joshi A, Gordon KB.) JAMA Dermatol. 2020 12 01;156(12):1344-1353 PMID: 33052382 PMCID: PMC7557488 SCOPUS ID: 2-s2.0-85094184750 10/15/2020
Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study.

(Reich K, Armstrong AW, Foley P, Song M, Miller M, Shen YK, You Y, Han C, Gordon KB.) Am J Clin Dermatol. 2020 Dec;21(6):881-890 PMID: 32910434 SCOPUS ID: 2-s2.0-85090788734 09/11/2020